Advanced search
Publication Cover
Expert Review of Hematology Volume 11, 2018 - Issue 4
Submit an article Journal homepage
1,528
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Therapy-free remission in chronic myeloid leukemia: possible mechanism

Robert Peter GaleHaematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, UKCorrespondence[email protected]
View further author information
&
Andreas HochhausAbteilung Hämatologie/Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, GermanyView further author information
Pages 269-272 | Received 18 Jan 2018, Accepted 14 Feb 2018, Published online: 09 Mar 2018

References

  • Hoyoake TL, Vetrie D. The chronic myeloid leukemia stem cell: stemming the tide of persistence. Blood. 2017;129:21595–21606.
  • Goldman JM, Melo JV. Chronic myeloid leukemia--advances in biology and new approaches to treatment. N Engl J Med. 2003;349:1451–1464.
  • Lukásová E, Kozubek S, Kozubek M, et al. Localization and distance between ABL and BCR genes in interphase nuclei of bone marrow cells of control donors and patients with chronic myeloid leukemia. Hum Genet. 1997;100:525–535.
  • Aurer I, Juhbashi T, Sekine I, et al. Analysis of BCR/ABL abnormalities in mRNA from 20-year-old paraffin-embedded tissue for BCR/ABL rearrangement by polymerase chain reaction. Acta Haematol. 1993;90:5–7.
  • Hsu WL, Preston DL, Soda M, et al. The incidence of leukemia, lymphoma and multiple myeloma among A-bomb survivors: 1950-2001. Radiat Res. 2013;179:361–382.
  • Dhut S, Chaplin T, Young BD. BCR-ABL and BCR proteins: biochemical characterization and localization. Leukemia. 1990;4:745–750.
  • Butturini A, Klein J, Gale RP. Modeling minimal residual disease (MRD)-testing. Leuk Res. 2003;27:293–300.
  • Alikian M, Gale RP, Apperley JF, et al. Molecular technique for the personalized management of patients with chronic myeloid leukemia. Biomol Detect Qualif. 2017;11:4–20.
  • Roeder I, Horn M, Glauche I, et al. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med. 2006;12:1181–1184.
  • Ross DM, Hughes TP, Melo JV. Do we have to kill the last CML cell? Leukemia. 2011;25:193–200.
  • Bose S, Deininger M, Gora-Tybor J, et al. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood. 1998 Nov 1;92(9):3362–3367.
  • Biernaux C, Loos M, Sels A, et al. Detection of major BCR-ABL gene expression at a very level in blood cells of some healthy individuals. Blood. 1995;86:3118.
  • Song J, Mercer D, Hu X, et al. Common leukemia-and lymphoma-associated genetic aberrations in healthy individuals. J Mol Diagn. 2011;13:213–219.
  • Goldman JM, Majhail NS, Klein JP. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. J Clin Oncol. 2010;28:1888–1895.
  • Ilander M, Olsson-Strömberg U, Schlums H, et al. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia. 2017;31:1108–1116.
  • Hughes A, Clarson I, Tang C, et al. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors. Blood. 2017;129:1166–1176.
  • Hughes A, Yong ASM. Immune effector recovery in chronic myeloid leukemia and treatment-free remission. Front Immunol. 2017;24(8):469.
  • Gale RP, Opelz G. Is there immune surveillance against chronic myeloid leukemia? Possibly, but not much. Leuk Res. 2017;57:109–111.
  • Seita J, Weissman IL. Hematopoietic stem cell: self-renewal versus differentiation. Wiley Interdiscip Rev Syst Biol Med. 2010;2:640–653.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.